Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

gMG is different from ocular myasthenia gravis, which only affects the eye muscles. “Anti-acetylcholine receptor (AChR) antibody-positive” means your immune system makes antibodies that block ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Generalized myasthenia gravis is a chronic autoimmune disease ... The main symptom of the disease is muscle weakness, including around the eyes, mouth, head and neck. FcRN spares antibodies ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include myasthenia gravis activities of daily living scale (MG-ADL) and quantitative myasthenia gravis (QMG) ...